CoChat
Sign Up
Cited by 146Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876

Open access
Ma, Yibao, Wang, Wei, Idowu, Michael O., Oh, Unsong, Wang, Xiang-Yang, Temkin, Sarah M., Fang, Xianjun·2018·Cancers
DOI 10.3390/cancers11010033PMC PMC6356953
Open this paper in CoChat — free accountOpen PDF

Abstract

The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies. However, therapeutic targeting of glycolysis to treat cancer remains unsuccessful due to complex mechanisms of tumor glycolysis and the lack of selective, potent and safe glycolytic inhibitors. Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer. Notably, BAY-876 has not been evaluated in any cell or preclinical animal models since its discovery. We herein took advantage of BAY-876 and molecular approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis. The anti-tumor activity of BAY-876 was evaluated with ovarian cancer cell line- and patient-derived xenograft (PDX) models. Our results show that inhibition of GLUT1 is sufficient to block basal and stress-regulated glycolysis, and anchorage-dependent and independent growth of ovarian cancer cells. BAY-876 dramatically inhibits tumorigenicity of both cell line-derived xenografts and PDXs. These studies provide direct evidence that GLUT1 is causally linked to the glycolytic phenotype in ovarian cancer. BAY-876 is a potent blocker of GLUT1 activity, glycolytic metabolism and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11010033

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Glucose transporter 1 (GLUT1) activity is required for maintenance of hyperactive glycolysis in ovarian cancer. Ovarian cancer cell lines were treated for 24 h with indicated concentrations of BAY-876. The glycolytic rate (A) and lactate concentrations in supernatants (B) were measured as described in Materials and Methods. The lactate levels are presented as mM concentrations present in 1 mL culture supernatants normalized to 5 × 105 cells over 24 h incubation. In (C) GLUT1 was silenced by siRNA in SKOV-3 and OVCAR-3 cells and effects of siRNA knockdown on glycolysis and lactate production were determined. For this and all the following figures, the data presented were mean ± SD of triplicates, representative of 3 independent experiments unless otherwise indicated. * p < 0.05; ** p < 0.01.
Figure 1 Glucose transporter 1 (GLUT1) activity is required for maintenance of hyperactive glycolysis in ovarian cancer. Ovarian cancer cell lines were treated for 24 h with indicated concentrations of BAY-876. The glycolytic rate (A) and lactate concentrations in supernatants (B) were measured as described in Materials and Methods. The lactate levels are presented as mM concentrations present in 1 mL culture supernatants normalized to 5 × 105 cells over 24 h incubation. In (C) GLUT1 was silenced by siRNA in SKOV-3 and OVCAR-3 cells and effects of siRNA knockdown on glycolysis and lactate production were determined. For this and all the following figures, the data presented were mean ± SD of triplicates, representative of 3 independent experiments unless otherwise indicated. * p < 0.05; ** p < 0.01.CC BY · PubMed Central
Figure 2 GLUT1 mediates hypoxia- and energy stress-induced glycolysis. Ovarian cancer cell lines were treated for 24 h with CoCl2 (150 µM) in the presence or absence of BAY-876 (75 nM) (A). In (B), Ovarian cancer cell lines were treated for 24 h with vehicle, metformin (2 mM), etomoxir (0.25 mM), or MNS-B (50 nM) in the absence or presence of BAY-876 (75 nM). Expression of GLUT1 and HIF-1α proteins was analyzed by immunoblotting. Glycolytic rates were quantified as in Figure 1. The statistical significances of glycolytic induction and BAY-876-dependent inhibition were indicated with red and black asterisks, respectively. n.s.: * p < 0.05; ** p < 0.01.
Figure 2 GLUT1 mediates hypoxia- and energy stress-induced glycolysis. Ovarian cancer cell lines were treated for 24 h with CoCl2 (150 µM) in the presence or absence of BAY-876 (75 nM) (A). In (B), Ovarian cancer cell lines were treated for 24 h with vehicle, metformin (2 mM), etomoxir (0.25 mM), or MNS-B (50 nM) in the absence or presence of BAY-876 (75 nM). Expression of GLUT1 and HIF-1α proteins was analyzed by immunoblotting. Glycolytic rates were quantified as in Figure 1. The statistical significances of glycolytic induction and BAY-876-dependent inhibition were indicated with red and black asterisks, respectively. n.s.: * p < 0.05; ** p < 0.01.CC BY · PubMed Central
Figure 3 Inhibition of GLUT1 decreases ATP, activates AMPK and enhances OCR. SKOV-3, OVCAR-3 and A2780 cells were treated with vehicle or BAY-876 (75 nM). Cellular ATP contents (nMol of ATP in 106 cells) (A), and levels of phosphorylated AMPKα (B) were determined with an ATP bioluminescence assay and immunoblotting analysis, respectively. In (C), OCR in these cell lines treated with vehicle or BAY-876 (75 nM) was measured with the Seahorse XF24 Analyzer as detailed in Materials and Methods. The background in cell-free wells was subtracted from readings of all other wells. The presented in upper panel were real time OCRs (pMoles/min, mean ± SD of triplicate assay) over the course of measurement. In lower panel, basal mitochondrial respiration (Basal), ATP-linked respiration (ATP-linked), maximal respiratory capacity (Maximum) and Reserve capacity were calculated and statistically analyzed to show the effects of BAY-876. * p < 0.05; ** p < 0.01.
Figure 3 Inhibition of GLUT1 decreases ATP, activates AMPK and enhances OCR. SKOV-3, OVCAR-3 and A2780 cells were treated with vehicle or BAY-876 (75 nM). Cellular ATP contents (nMol of ATP in 106 cells) (A), and levels of phosphorylated AMPKα (B) were determined with an ATP bioluminescence assay and immunoblotting analysis, respectively. In (C), OCR in these cell lines treated with vehicle or BAY-876 (75 nM) was measured with the Seahorse XF24 Analyzer as detailed in Materials and Methods. The background in cell-free wells was subtracted from readings of all other wells. The presented in upper panel were real time OCRs (pMoles/min, mean ± SD of triplicate assay) over the course of measurement. In lower panel, basal mitochondrial respiration (Basal), ATP-linked respiration (ATP-linked), maximal respiratory capacity (Maximum) and Reserve capacity were calculated and statistically analyzed to show the effects of BAY-876. * p < 0.05; ** p < 0.01.CC BY · PubMed Central
Figure 4 GLUT1 activity is crucial for cell growth. SKOV-3, OVCAR-3, HEY, and A2780 were cultured in 12-well plates with or without BAY-876 at indicated concentrations. The effects of BAY-876 on cell proliferation were analyzed by determination of cell numbers after 24 h (A) and 72-h growth curves (B). In (C), ovarian cancer cell lines were treated with indicated concentrations of BAY-876 for 72 h before the MTT assay to determine the cytotoxic effect of the compound. IC50 in each cell line was calculated using SigmaPlot 13.0 (Systat Software, San Jose, CA, USA). The effects of BAY-876 (75 nM for SKOV-3 and OVCAR-3, and 200 nM for the less sensitive HEY) on anchorage-independent growth were determined by soft agar assay (D). The data was presented as number of colonies per well. * p < 0.05; ** p < 0.01.
Figure 4 GLUT1 activity is crucial for cell growth. SKOV-3, OVCAR-3, HEY, and A2780 were cultured in 12-well plates with or without BAY-876 at indicated concentrations. The effects of BAY-876 on cell proliferation were analyzed by determination of cell numbers after 24 h (A) and 72-h growth curves (B). In (C), ovarian cancer cell lines were treated with indicated concentrations of BAY-876 for 72 h before the MTT assay to determine the cytotoxic effect of the compound. IC50 in each cell line was calculated using SigmaPlot 13.0 (Systat Software, San Jose, CA, USA). The effects of BAY-876 (75 nM for SKOV-3 and OVCAR-3, and 200 nM for the less sensitive HEY) on anchorage-independent growth were determined by soft agar assay (D). The data was presented as number of colonies per well. * p < 0.05; ** p < 0.01.CC BY · PubMed Central
Figure 5 BAY-876 inhibits growth of SKOV-3 xenografts in mice. Four groups of female NSG mice bearing SKOV-3 xenografts were treated with BAY-876 for 28 days at dose of 0, 1.5, 3, or 4.5 mg/kg/day. Data shown were growth curves of tumor volumes (A), body weights over the course of experiment (B), images of end point tumors and final tumor weights (C). The data of all animal experiments were presented as mean ± SD. ** p < 0.01.
Figure 5 BAY-876 inhibits growth of SKOV-3 xenografts in mice. Four groups of female NSG mice bearing SKOV-3 xenografts were treated with BAY-876 for 28 days at dose of 0, 1.5, 3, or 4.5 mg/kg/day. Data shown were growth curves of tumor volumes (A), body weights over the course of experiment (B), images of end point tumors and final tumor weights (C). The data of all animal experiments were presented as mean ± SD. ** p < 0.01.CC BY · PubMed Central
Figure 6 BAY-876 suppresses ovarian cancer PDXs in mice. Two serous ovarian carcinoma PDXs grown s.c. in female NSG mice were treated for 30 days with BAY-876 (4 mg/kg/day). Data shown were growth curves of tumor volumes (A,E), body weights over the course of experiment (B,F), images and weights of end point xenografts (C,G) and immunoblotting analysis of GLUT1 protein expression in PDXs from 3 vehicle- and 3 BAY-876-treated mice (D,H). ** p < 0.01.
Figure 6 BAY-876 suppresses ovarian cancer PDXs in mice. Two serous ovarian carcinoma PDXs grown s.c. in female NSG mice were treated for 30 days with BAY-876 (4 mg/kg/day). Data shown were growth curves of tumor volumes (A,E), body weights over the course of experiment (B,F), images and weights of end point xenografts (C,G) and immunoblotting analysis of GLUT1 protein expression in PDXs from 3 vehicle- and 3 BAY-876-treated mice (D,H). ** p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. Warburg, 1924, üeber den Stoffwechsel der Tumoren, Biochem. Z., 152, 319

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Ma, Y., Wang, W., Idowu, M. O., Oh, U., Wang, X.-Y., Temkin, S. M., & Fang, X.
Affiliations
Virginia Commonwealth University (US)
Corresponding author
Fang, Xianjun
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2018-12-31
Volume
11
Issue
1
Pages
33
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers11010033
PMC
PMC6356953
OpenAlex
W2907710771
Cited by
145
References
51
Citations by year
2026: 14 · 2025: 15 · 2024: 21 · 2023: 25 · 2022: 18 · 2021: 27 · 2020: 9 · 2019: 14
FWCI
3.85
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (P30 CA16059)
  • Astar Biotechnology Research award (N/A)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
ovarian cancer, glucose transporter 1, GLUT1, BAY-876, glycolysis, cancer metabolism, glycolysis inhibitors, tumor growth, patient-derived xenografts, anchorage-independent growth, anticancer activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review